Knock, knock: who's there?: Nox1.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation

• Publication date

  2013-05-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.113.002564PMID 23564667PMCID PMC3909710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

  2013cited by this paper
• Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

  2012cited by this paper
• Biochemistry, Physiology, and Pathophysiology of NADPH Oxidases in the Cardiovascular System

  2012cited by this paper
• The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

  2012cited by this paper
• First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.

  2010cited by this paper
• Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling.

  2010cited by this paper
• Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

  2008cited by this paper
• Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease.

  2008cited by this paper
• Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.

  2005cited by this paper
• Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice

  2005cited by this paper
• Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle.

  2005cited by this paper
• Novel NAD(P)H Oxidase Inhibitor Suppresses Angioplasty-Induced Superoxide and Neointimal Hyperplasia of Rat Carotid Artery

  2003cited by this paper
• The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

  2003cited by this paper
• MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Vitamin E supplementation and cardiovascular events in high-risk patients.

  2000cited by this paper
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

  1999cited by this paper
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

  1999cited by this paper
• Antioxidant properties of clozapine and related neuroleptics.

  1998cited by this paper
• A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor.

  1998cited by this paper
• Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I).

  1994cited by this paper

• Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

  2014cites this paper